Caitlin Lowie - Solid Biosciences VP IR
| SLDB Stock | USD 5.69 0.09 1.56% |
Insider
Caitlin Lowie is VP IR of Solid Biosciences LLC
| Address | 500 Rutherford Avenue, Charlestown, MA, United States, 02129 |
| Phone | 617 337 4680 |
| Web | https://www.solidbio.com |
Solid Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3533) % which means that it has lost $0.3533 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6579) %, meaning that it created substantial loss on money invested by shareholders. Solid Biosciences' management efficiency ratios could be used to measure how well Solid Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.61. In addition to that, Return On Capital Employed is expected to decline to -0.73. At present, Solid Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 135.9 M, whereas Total Assets are forecasted to decline to about 152.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
| David Pompliano | Revolution Medicines | N/A | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Michelle Corral | Alector | N/A | |
| Elizabeth Montgomery | Black Diamond Therapeutics | 52 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Michael Fischbach | Revolution Medicines | 43 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| David Mack | Pmv Pharmaceuticals | 62 | |
| TaiAn Lin | Black Diamond Therapeutics | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Simona King | Passage Bio | 52 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 |
Solid Biosciences LLC Leadership Team
Elected by the shareholders, the Solid Biosciences' board of directors comprises two types of representatives: Solid Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Solid. The board's role is to monitor Solid Biosciences' management team and ensure that shareholders' interests are well served. Solid Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Solid Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alexander Cumbo, CEO President | ||
| Gabriel MD, Chief Officer | ||
| Gilad Hayeem, President Co-Founder, Director | ||
| Shuli MD, Head Development | ||
| Ilan Ganot, CEO, Co-Founder, Director | ||
| Paul Herzich, Chief Officer | ||
| Caitlin Lowie, VP IR | ||
| Matthew Arnold, Independent Director | ||
| Allison JD, Senior Resources | ||
| Carl Morris, Chief Scientific Officer | ||
| Kevin CFA, CFO Treasurer | ||
| ACA ACA, Ex Chair | ||
| Andrey Zarur, Chairman of the Board, Co-Founder | ||
| Erin Brennan, Chief Sec | ||
| JD Howton, Chief Officer | ||
| MBA MBA, Treasurer CFO | ||
| CPA ACA, Executive Chair | ||
| Stephen MBA, Treasurer Officer | ||
| Annie Ganot, CoFounder Advocacy | ||
| Jessie Hanrahan, Chief Officer |
Solid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Solid Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 80.94 M | ||||
| Shares Outstanding | 39.95 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 90.06 % | ||||
| Number Of Shares Shorted | 1.52 M | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | 13.62 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.